Mouse anti CD22 conjugated to FITC
Product Code:
GM-4052
GM-4052
Host Type:
Mouse
Mouse
Antibody Isotype:
IgG1
IgG1
Antibody Clonality:
Monoclonal
Monoclonal
Antibody Clone:
RFB4
RFB4
Regulatory Status:
RUO
RUO
Target Species:
Human
Human
Applications:
- Flow Cytometry
- Immunofluorescence (IF)
Storage:
Nordic-MUbio monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8°C (DO NOT FREEZE!) and protec
Nordic-MUbio monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8°C (DO NOT FREEZE!) and protec
No additional charges, what you see is what you pay! *
Code | Size | Price |
---|
GM-4052 | 2ml (100 Tests) | £317.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Netherlands.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Applications Description:
Staining Procedure for Surface CD22:
Direct Immunofluorescence (Staining Procedure) Nordic-MUbio fluorochrome labeled antibodies are designed for use with either whole blood or isolated mononuclear cell (MNC) preparations
Proposed staining procedure for whole blood in short:
- For each sample add 50 ?l of EDTA anti-coagulated blood to a 3-5 ml tube
- Add 20 ?l of the appropriate Nordic-MUbio monoclonal antibody conjugate
- Incubate the tube for 15 minutes at 4°C or at room temperature in the dark
- Add 100 ?l Nordic-MUbio-LYSE (Cat.No. GAS-003) to each tube and incubate for 10 minutes at room temperature - Add 3-4 ml of destilled water and vortex, incubate for 5-10 minutes at room temperature
- Centrifuge tube for 5 minutes at 300 g
- Aspirate supernatant and resuspend pellet in 0.3 ml of sheath fluid
- Analyze immediately or store samples at 2-8° C in the dark and analyze within 24 hours
For ?No-Wash? protocol please refer to www.nordicmubio.com
Proposed staining procedure for MNC in short:
- Carefully add 20 ?l antibody conjugate and 50-100 ?l MNC to the bottom of a tube
- Vortex at low speed for 1-2 seconds
- Incubate for 15-30 minutes at 2-8°C or at room temperature
- Centrifuge tubes for 5 minutes at 300 g
- Remove supernatant, resuspend cells in 2-5 ml of phosphate buffered saline (PBS) and centrifuge cells again for 5 minutes at 300 g
- Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1 % formaldehyde and store them at 2-8°C in the dark.
- Analyze fixed cells within 24 hours
Indirect Immunofluorescence (Staining Procedure)
- Mix 20 ?l Nordic-MUbio purified antibody with 50 ?l whole blood or MNC suspension
- Incubate for 15 minutes at 2-8°C
- Wash cells with phosphate buffered saline (PBS)
- Add to cell pellet 20 ?l of affinity purified, fluorochrome labeled F(ab?)2 anti mouse Ig antibodies
- Incubate for 15 minutes at 2-8°C
- Wash cells with phosphate buffered saline (PBS) or proceed as described for direct staining
Staining Procedure for Cytoplasmatic CD22: Permeabilization and Staining Procedure
- In combination with our Permeabilization Kit FIX&PERM? (Cat. No. GAS-002) intracellular CD22 can be easily stained in cell suspensions.
- For each sample to be analyzed add 50 ?l of whole blood, bone marrow or mononuclear cell suspension in a 5ml tube
- Add 100 ?l of Reagent A (Fixation Medium, stored and used at room temperature)
- Incubate for 15 minutes at room temperature
- Add 5ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g
- Remove supernatant and add to cell pellet 100 ?l Reagent B (Permeabilization Medium) and 20 ?l of the CD22 monoclonal antibody conjugate
- Vortex at low speed for 1-2 seconds
- Incubate for 15 minutes at room temperature
- Wash cells with phosphate buffered saline as described above
- Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2- 8°C in the dark.
- Analyze fixed cells within 24 hours.
Direct Immunofluorescence (Staining Procedure) Nordic-MUbio fluorochrome labeled antibodies are designed for use with either whole blood or isolated mononuclear cell (MNC) preparations
Proposed staining procedure for whole blood in short:
- For each sample add 50 ?l of EDTA anti-coagulated blood to a 3-5 ml tube
- Add 20 ?l of the appropriate Nordic-MUbio monoclonal antibody conjugate
- Incubate the tube for 15 minutes at 4°C or at room temperature in the dark
- Add 100 ?l Nordic-MUbio-LYSE (Cat.No. GAS-003) to each tube and incubate for 10 minutes at room temperature - Add 3-4 ml of destilled water and vortex, incubate for 5-10 minutes at room temperature
- Centrifuge tube for 5 minutes at 300 g
- Aspirate supernatant and resuspend pellet in 0.3 ml of sheath fluid
- Analyze immediately or store samples at 2-8° C in the dark and analyze within 24 hours
For ?No-Wash? protocol please refer to www.nordicmubio.com
Proposed staining procedure for MNC in short:
- Carefully add 20 ?l antibody conjugate and 50-100 ?l MNC to the bottom of a tube
- Vortex at low speed for 1-2 seconds
- Incubate for 15-30 minutes at 2-8°C or at room temperature
- Centrifuge tubes for 5 minutes at 300 g
- Remove supernatant, resuspend cells in 2-5 ml of phosphate buffered saline (PBS) and centrifuge cells again for 5 minutes at 300 g
- Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1 % formaldehyde and store them at 2-8°C in the dark.
- Analyze fixed cells within 24 hours
Indirect Immunofluorescence (Staining Procedure)
- Mix 20 ?l Nordic-MUbio purified antibody with 50 ?l whole blood or MNC suspension
- Incubate for 15 minutes at 2-8°C
- Wash cells with phosphate buffered saline (PBS)
- Add to cell pellet 20 ?l of affinity purified, fluorochrome labeled F(ab?)2 anti mouse Ig antibodies
- Incubate for 15 minutes at 2-8°C
- Wash cells with phosphate buffered saline (PBS) or proceed as described for direct staining
Staining Procedure for Cytoplasmatic CD22: Permeabilization and Staining Procedure
- In combination with our Permeabilization Kit FIX&PERM? (Cat. No. GAS-002) intracellular CD22 can be easily stained in cell suspensions.
- For each sample to be analyzed add 50 ?l of whole blood, bone marrow or mononuclear cell suspension in a 5ml tube
- Add 100 ?l of Reagent A (Fixation Medium, stored and used at room temperature)
- Incubate for 15 minutes at room temperature
- Add 5ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g
- Remove supernatant and add to cell pellet 100 ?l Reagent B (Permeabilization Medium) and 20 ?l of the CD22 monoclonal antibody conjugate
- Vortex at low speed for 1-2 seconds
- Incubate for 15 minutes at room temperature
- Wash cells with phosphate buffered saline as described above
- Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2- 8°C in the dark.
- Analyze fixed cells within 24 hours.
Background:
The epitope recognized by antibody RFB4 is a 135 kDa type I integral membrane protein expressed by human B-cells. Precursor B-cells are surface-CD22 negative, but cytoplasmic CD22 positive. Mature B-lymphocytes express CD22 also on their surface.
The RFB4 antibody permits the identification and enumeration of human B-cells using flow cytometry. Results must be put within the context of other diagnostic tests as well
as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
The RFB4 antibody permits the identification and enumeration of human B-cells using flow cytometry. Results must be put within the context of other diagnostic tests as well
as the clinical history of the patient by a certified professional before final interpretation. Analyses performed with this antibody should be paralleled by positive and negative controls. If unexpected results are obtained which cannot be attributed to differences in laboratory procedures, please contact us.
Caution:
For professional users only.
This reagent contains sodium azide. To avoid the development
of hazardous conditions, reagents containing azide should be
diluted in running water prior to be discarded. Similar to the work
with other biological products, proper handling procedures are
recommended.
This reagent contains sodium azide. To avoid the development
of hazardous conditions, reagents containing azide should be
diluted in running water prior to be discarded. Similar to the work
with other biological products, proper handling procedures are
recommended.
Formulation:
Purified by Chromatography, Storage buffer: PBS pH 7.2, 1% BSA, 0.05% NaN3
Label:
FITC
Product:
2 ml of FITC-conjugated anti CD22 (clone RFB4) in PBS pH 7.2, 1% BSA, and 0.05% NaN3, approximately 100 tests.
Product Form:
FITC
Purification Method:
Purified by Chromatography
Specificity:
The CD22 mAb (clone RFB4) recognizes surface CD22 expressed by mature peripheral B-cells and cytoplasmatic CD22 expressed by precursor B-cells.
The sensitivity of RFB4 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity).For this purpose, a mAb-concentration
range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect an identical percentage of cells). In practice, 50 ?l of leukocytes containing 10^7 cells/ml are stained with 20 ?l mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.
The sensitivity of RFB4 mAb is determined by staining well-defined blood samples from representative donors with serial-fold mAb dilutions to obtain a titration curve that allows relating the mAb concentration to the percentage of stained cells and geometric MFI (mean fluorescence intensity).For this purpose, a mAb-concentration
range is selected to include both the saturation point (i.e. the mAb dilution expected to bind all epitopes on the target cell) and the detection threshold (i.e. the mAb dilution expected to represent the least amount of mAb needed to detect an identical percentage of cells). In practice, 50 ?l of leukocytes containing 10^7 cells/ml are stained with 20 ?l mAb of various dilutions to obtain a titration curve and to identify the saturation point and detection threshold. The final concentration of the product is then adjusted to be at least 3-fold above the detection threshold. In addition and to control lot-to-lot variation, the given lot is compared and adjusted to fluorescence standards with defined intensity.
UniProt:
P20273
Documents
References
1. Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83.
2.
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7.
3. Lanza, F., Latorraca, A., Moretti, S., Castagnari, B., Ferrari, L. & Castoldi, G. (1997) Cytometry 30, 134-44.
4.
Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9.
5.
Wilson, G. L., Fox, C. H., Fauci, A. S. & Kehrl, J. H. (1991) J Exp Med 173, 137-46.
6.
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
7. Stamenkovic, I. & Seed, B. (1990) Nature 345, 74-7.
8. Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
9. Li, J. L., Shen, G. L., Ghetie, M. A., May, R. D., Till, M., Ghetie, V., Uhr, J. W., Janossy, G., Thorpe, P. E., Amlot, P. & et al. (1989)
Cell Immunol 118, 85-99.
10.
Schwartz-Albiez, R., Dorken, B. & Moldenhauer, G. (1989) In Leukocyte Typing IV (Oxford University Press, Oxford) p65-7.
11.
Pezzutto, A., Rabinovitch, P. S., Dorken, B., Moldenhauer, G. & Clark, E. A. (1988) J Immunol 140, 1791-5.
12. Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8.
13. Boue, D. R. & Lebien, T. W. (1988) J Immunol 140, 192-9.
14.
Mason, D. Y., Stein, H., Gerdes, J., Pulford, K. A., Ralfkiaer, E., Falini, B., Erber, W. N., Micklem, K. & Gatter, K. C. (1987) Blood
69, 836-40.
15. Pezzutto, A., Dorken, B., Moldenhauer, G. & Clark, E. A. (1987) J Immunol 138, 98-103.
16. van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40.
17. Dorken, B., Moldenhauer, G., Pezzutto, A., Schwartz, R., Feller, A., Kiesel, S. & Nadler, L. M. (1986) J Immunol 136, 4470-9.
18.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13.
2.
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7.
3. Lanza, F., Latorraca, A., Moretti, S., Castagnari, B., Ferrari, L. & Castoldi, G. (1997) Cytometry 30, 134-44.
4.
Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9.
5.
Wilson, G. L., Fox, C. H., Fauci, A. S. & Kehrl, J. H. (1991) J Exp Med 173, 137-46.
6.
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
7. Stamenkovic, I. & Seed, B. (1990) Nature 345, 74-7.
8. Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
9. Li, J. L., Shen, G. L., Ghetie, M. A., May, R. D., Till, M., Ghetie, V., Uhr, J. W., Janossy, G., Thorpe, P. E., Amlot, P. & et al. (1989)
Cell Immunol 118, 85-99.
10.
Schwartz-Albiez, R., Dorken, B. & Moldenhauer, G. (1989) In Leukocyte Typing IV (Oxford University Press, Oxford) p65-7.
11.
Pezzutto, A., Rabinovitch, P. S., Dorken, B., Moldenhauer, G. & Clark, E. A. (1988) J Immunol 140, 1791-5.
12. Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8.
13. Boue, D. R. & Lebien, T. W. (1988) J Immunol 140, 192-9.
14.
Mason, D. Y., Stein, H., Gerdes, J., Pulford, K. A., Ralfkiaer, E., Falini, B., Erber, W. N., Micklem, K. & Gatter, K. C. (1987) Blood
69, 836-40.
15. Pezzutto, A., Dorken, B., Moldenhauer, G. & Clark, E. A. (1987) J Immunol 138, 98-103.
16. van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40.
17. Dorken, B., Moldenhauer, G., Pezzutto, A., Schwartz, R., Feller, A., Kiesel, S. & Nadler, L. M. (1986) J Immunol 136, 4470-9.
18.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13.